Core Insights - CervoMed Inc. has granted equity awards to two new employees as a material inducement for their employment [1][2] - The company is focused on developing treatments for age-related neurologic disorders, specifically through its investigational drug neflamapimod [3] Summary by Sections Equity Awards - On December 6, 2024, CervoMed granted options to purchase a total of 14,753 shares of common stock to two new employees, with an exercise price of $11.91, which is the closing price on the grant date [2] - The options will vest in 36 equal installments over three years, contingent on the employees' continued employment [2] Company Overview - CervoMed Inc. is a clinical-stage company dedicated to developing treatments for age-related neurologic disorders [3] - The company is currently working on neflamapimod, an orally administered small molecule designed to inhibit p38 mitogen-activated protein kinase alpha, which may address synaptic dysfunction in neurodegenerative diseases [3]
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)